ThermoStem
Obesity, Type 2 Diabetes
PreclinicalResearch & Development
Key Facts
Indication
Obesity, Type 2 Diabetes
Phase
Preclinical
Status
Research & Development
Company
About BioRestorative Therapies
BioRestorative Therapies is a micro-cap biotech focused on developing regenerative therapies using adult stem cells to address conditions with high unmet medical need. Its core strategy balances a high-risk, high-reward clinical pipeline targeting chronic pain and metabolic disorders with a commercial cosmeceutical division for near-term revenue. Key achievements include the ongoing Phase 2 trial for BRTX-100 in chronic lumbar disc disease and the establishment of its scientific platform. The company's mission is to leverage the body's intrinsic repair mechanisms to improve patient outcomes in large, underserved markets.
View full company profileTherapeutic Areas
Other Obesity, Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Danuglipron (GLP-1/GIP) | Pfizer | Phase 3 |
| PF-07081532 (GLP-1R) | Pfizer | Phase 3 |
| CagriSema (Subcutaneous) | Novo Nordisk | Phase 3 |
| Oral CagriSema | Novo Nordisk | Phase 2 |